A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint

被引:0
作者
Qing, Yun [1 ,2 ]
Thall, Peter F. [1 ]
Yuan, Ying [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA
关键词
Bayesian adaptive design; futility monitoring; go; no-go decision; interim analysis; OPTIMAL 2-STAGE DESIGNS; CLINICAL-TRIALS; SURVIVAL; SAMPLE;
D O I
10.1002/pst.2256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [21] BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints
    Bi, Dehua
    Liu, Meizi
    Lin, Jianchang
    Liu, Rachael
    STATISTICS IN MEDICINE, 2023, 42 (30) : 5708 - 5722
  • [22] Bayesian design of clinical trials with multiple time-to-event outcomes subject to functional cure
    Cho, Seoyoon
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2025,
  • [23] Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data
    Le Coent, Quentin
    Legrand, Catherine
    Rondeau, Virginie
    BIOSTATISTICS, 2023, 25 (01) : 98 - 116
  • [24] Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards
    Sharma, Palash
    Phadnis, Milind A.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024, 34 (04) : 596 - 611
  • [25] Doubly adaptive biased coin design to improve Bayesian clinical trials with time-to-event endpoints
    Cao, Wenhao
    Zhu, Hongjian
    Wang, Li
    Zhang, Lixin
    Yu, Jun
    STATISTICS IN MEDICINE, 2024, 43 (09) : 1743 - 1758
  • [26] Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter
    Waleed, Muhammad
    He, Jianghua
    Phadnis, Milind A.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024, 34 (04) : 469 - 487
  • [27] A bi-endpoint expectation-maximisation algorithm for re-estimating sample size for the time-to-event endpoint under the blind condition
    Xie, Longshen
    Lu, Hui
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2024, 73 (04) : 935 - 954
  • [28] A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
    Guenhan, Burak Kuersad
    Weber, Sebastian
    Friede, Tim
    STATISTICS IN MEDICINE, 2020, 39 (27) : 3986 - 4000
  • [29] Bayesian Design of Clinical Trials Using Joint Cure Rate Models for Longitudinal and Time-to-Event Data
    Jiawei Xu
    Matthew A. Psioda
    Joseph G. Ibrahim
    Lifetime Data Analysis, 2023, 29 : 213 - 233
  • [30] Bayesian decision sequential analysis with survival endpoint in phase II clinical trials
    Zhao, Lili
    Woodworth, George
    STATISTICS IN MEDICINE, 2009, 28 (09) : 1339 - 1352